Legend Biotech CorpLEGNEarnings & Financial Report
GenScript Biotech, fully known as GenScript Biotech Corporation, usually referred to as simply GenScript, is a China–based biotech company. It was co-founded in 2002 in New Jersey by Fangliang Zhang, Ye Wang, and Luquan Wang. The company mainly provides life science research application instruments and services. It was listed on the Hong Kong Stock Exchange in 2015. The current rotating CEO of the firm is Shao Weihui, who also served as the chief operating officer and Chinese Communist Party ...
Revenue
$186.5M
Gross Profit
$141.2M
Operating Profit
N/A
Net Profit
$-18.2M
Gross Margin
75.7%
Operating Margin
N/A
Net Margin
-9.8%
YoY Growth
154.4%
EPS
$-0.05
Legend Biotech Corp Q2 FY2024 Financial Summary
Legend Biotech Corp reported revenue of $186.5M (up 154.4% YoY) for Q2 FY2024, with a net profit of $-18.2M (up 90.9% YoY) (-9.8% margin). Cost of goods sold was $45.4M.
Key Financial Metrics
| Total Revenue | $186.5M |
|---|---|
| Net Profit | $-18.2M |
| Gross Margin | 75.7% |
| Operating Margin | N/A |
| Report Period | Q2 FY2024 |
Legend Biotech Corp Quarterly Revenue & Net Profit History
Legend Biotech Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $272.3M | +70.0% | $-39.7M | -14.6% |
| Q2 FY2025 | $255.1M | +36.7% | $-125.4M | -49.2% |
| Q1 FY2025 | $195.1M | +107.5% | $-100.9M | -51.7% |
| Q3 FY2024 | $160.2M | +66.9% | $-125.3M | -78.2% |
| Q2 FY2024 | $186.5M | +154.4% | $-18.2M | -9.8% |
| Q1 FY2024 | $94.0M | +158.7% | $-59.8M | -63.6% |
| Q3 FY2023 | $96.0M | — | $-62.2M | -64.8% |
| Q2 FY2023 | $73.3M | — | $-199.1M | -271.6% |
Income Statement
| Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $73.3M | $96.0M | $94.0M | $186.5M | $160.2M | $195.1M | $255.1M | $272.3M |
| YoY Growth | N/A | N/A | 158.7% | 154.4% | 66.9% | 107.5% | 36.7% | 70.0% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.93B | $1.84B | $1.78B | $1.80B | $1.74B | $1.62B | $1.69B | $1.71B |
| Liabilities | $523.6M | $499.7M | $611.0M | $639.2M | $619.7M | $597.9M | $654.4M | $701.7M |
| Equity | $1.41B | $1.34B | $1.16B | $1.16B | $1.12B | $1.02B | $1.04B | $1.01B |
Cash Flow
| Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-97.6M | $-60.8M | $15.5M | $-1.7M | $-75.8M | $-103.8M | $-13.0M | $28.8M |